Who is sponsoring NCT01730872?

NCT01730872 is sponsored by ORA, Inc..

What condition does NCT01730872 study?

NCT01730872 studies Chronic Allergic Conjunctivitis.

What drugs are being tested in NCT01730872?

Interventions: Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution.

What is the status of NCT01730872?

NCT01730872 is currently COMPLETED.

Last reviewed 2019-06-18 · How we verify

A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model

NCT01730872 Phase 4 COMPLETED Results posted

The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: Chronic Allergic Inflammation assessed using confocal microscopy Ocular itching Conjunctival redness

Details

Lead sponsor	ORA, Inc.
Phase	Phase 4
Status	COMPLETED
Enrolment	16
Start date	2012-11
Completion	2012-12

Conditions

Chronic Allergic Conjunctivitis

Interventions

Prednisolone Sodium Phosphate Ophthalmic Solution 1%
Tears Naturale II Ophthalmic Solution

Primary outcomes

Inflammation Change From Baseline to Day 6 — 90 minutes post CAC
Ocular inflammation was measured by a masked clinician on a 4-point scale 90 minutes after the conjunctival allergen challenge (CAC) . 0 = best (little to no inflammation), 4 = worst (most inflammation).

Countries

United States